Luxeptinib is a Small Molecule owned by CrystalGenomics, and is involved in 2 clinical trials, which are ongoing.

CG-806 acts by inhibiting fms-like dual tyrosine kinase (FLT3) and Brew button tyrosine kinase (bruton tyrosine kinase, BTK). Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies. FLT3 is overexpressed at the level of RNA and protein in most B lineage and acute myeloid leukemias. The drug candidate by inhibititng both FLT3 and BTK treats the cancer.

The revenue for Luxeptinib is expected to reach a total of $416m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Luxeptinib NPV Report.

Luxeptinib is originated and owned by CrystalGenomics. Aptose Biosciences is the other company associated in development or marketing of Luxeptinib.

Luxeptinib Overview

CG-806 is under development for the treatment of relasped/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), r/r chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom Macroglobulinemia, mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. It is a pan-FLT3/BTK inhibitor and act by targeting FLT3 (FMS-like tyrosine kinase 3) and brew button tyrosine kinase (bruton tyrosine kinase, BTK) along with CSF1R, PDGFRα, TRK, AURK, others. It is administered through the oral route. The drug candidate is developed based on a combination of soluble protein solution (SPS), structural chemo proteomics (SCP), structural-based drug factory (SDF) platforms.

Aptose Biosciences Overview

Aptose Biosciences (Aptose) is a clinical-stage biotechnology company that focuses on developing personalized therapies for the treatment of life-threatening cancers including, acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), certain B-cell malignancies, and other hematologic malignancies. The company’s cancer therapeutics pipeline products include HM43239, a myeloid kinome inhibitor (MKI), CG-806, a FLT3/BTK kinase inhibitor; APTO-253, a MYC oncogene inhibitor and APL-581, a dual BET Bromodomain-Kinase Inhibitor. Its small molecule cancer therapeutics pipeline product programs are designed to provide single agent benefit. The company operates in Canada and the US and has collaborations with biopharmaceutical companies and healthcare centers for the development and commercialization of its pipeline product programs. Aptose is headquartered in San Diego, California, the US.

The operating loss of the company was US$65.5 million in FY2021, compared to an operating loss of US$55.8 million in FY2020. The net loss of the company was US$65.4 million in FY2021, compared to a net loss of US$55.2 million in FY2020.

Quick View – Luxeptinib

Report Segments
  • Innovator
Drug Name
  • Luxeptinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.